Regentis Biomaterials Ltd. announced that the Japan Patent Office has issued a Notice of Allowance for its proprietary organic solvent-free manufacturing process and liquid formulation used in GelrinC, its regenerative treatment for articular cartilage injuries. This technology provides a 5x increase in yield and improved process efficiency. The company is currently advancing commercialization in Europe and conducting a pivotal U.S. FDA study with over 50% enrollment. Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions.
